Impact of highly active antiretroviral therapy on plasma MCP-1 and MSP in AIDS patients.
- Author:
Hang-Ping YAO
1
;
Chang-Zhong JIN
;
Fu-Jie ZHANG
;
Lei FENG
;
Hong-Shan WEI
;
Ling-Jiao WU
;
Gui-Ju GAO
;
Bader ARMIN
;
Brockmeyer NORBERT
;
Nan-Ping WU
Author Information
- Publication Type:Journal Article
- MeSH: Acquired Immunodeficiency Syndrome; blood; drug therapy; Adult; Anti-HIV Agents; therapeutic use; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemokine CCL2; blood; Enzyme-Linked Immunosorbent Assay; Female; Humans; Macrophage-Activating Factors; blood; Male; Middle Aged; Time Factors; Treatment Outcome
- From: Journal of Zhejiang University. Medical sciences 2007;36(2):174-178
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effect of highly active antiretroviral therapy (HAART) on plasma levels of MSP and MCP-1 in AIDS patients.
METHODSForty Chinese AIDS patients were treated with HAART for 3 months and 84 German AIDS patients with HAART for 3 to 6 years. The pre-treatment and post-treatment plasma levels of MSP and MCP-1 were measured by enzyme-linked immunosorbent assay (ELISA), and their correlations with CD4+ cell counts and viral loads were analyzed.
RESULTThe mean levels of MCP-1 were significantly higher and MSP were significantly lower in HIV-infected patients compared with the HIV-negative controls (P <0.01). After HAART for three months, there were no significant changes in the levels of these cytokines. But after long-term HAART (for 3 to 6 y), the level of MCP-1 was increased and that of MSP decreased significantly (P<0.01). There was a negative correlation between MSP and MCP-1 levels, and the same for MSP level and CD4+ cell counts; while there was a positive correlation between MCP-1 levels and CD4+ cell counts.
CONCLUSIONThe changed plasma levels of MSP and MCP-1 are associated with HIV-1 infection and HAART may reverse the levels of these two cytokines.
